Genmab A/S（GMAB）財務資料GMABGenmab A/S

Genmab A/S (GMAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 83.6% of total sales, equivalent to $966.00M. Other significant revenue streams include Net product sales and Collaboration revenue. Understanding this composition is critical for investors evaluating how GMAB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Genmab A/S maintains a gross margin of 92.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 35.24%, while the net margin is 26.23%. These profitability ratios, combined with a Return on Equity (ROE) of 14.00%, provide a clear picture of how effectively GMAB converts its operational activities into shareholder value.

In the context of the broader market, GMAB competes directly with industry leaders such as GILD and MRNA. With a market capitalization of $22.17B, it holds a significant position in the sector. When comparing efficiency, GMAB's gross margin of 92.73% stands against GILD's 79.76% and MRNA's 64.14%. Such benchmarking helps identify whether Genmab A/S is trading at a premium or discount relative to its financial performance.

Genmab has shown strong financials with a gross margin of 92.73% in Q2 2026 and a net margin of 26.23%, indicating efficient operations and profitability. The company has reported a year-to-date change of +16.50%, reflecting positive market sentiment.